WHAT IS THE CADTH REIMBURSEMENT RECOMMENDATION FOR CAMZYOS?: CADTH recommends that Camzyos be reimbursed by public drug plans for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II to III in adult patients if certain conditions are met. WHICH PATIENTS ARE ELIGIBLE FOR COVERAGE? Camzyos should only be covered to treat patients who have a documented left ventricular ejection fraction (LVEF) of 55% or greater at rest, determined by echocardiography, a left ventricular (LV) wall thickness of 15 mm or more (or ≥ 13 mm with a family history of hypertrophic cardiomyopathy [HCM]), and a left ventricular outflow tract (LVOT) peak gradient of 50 mm Hg or greater at rest, after Valsalva maneuver, or postexercise as confirmed by echocardiography. To be eligible, patients must also experience either worsening of symptoms or echocardiographically demonstrated deterioration while taking a beta-blocker (BB) or calcium channel blocker (CCB). WHAT ARE THE CONDITIONS FOR REIMBURSEMENT? Camzyos should only be reimbursed if patients are under the care of a cardiologist and if the cost of Camzyos is reduced. WHY DID CADTH MAKE THIS RECOMMENDATION? Evidence from the EXPLORER-HCM clinical trial demonstrated that NYHA class and peak oxygen consumption (pVO) improved in patients with symptomatic oHCM who were treated with Camzyos. Evidence from the VALOR-HCM clinical trial demonstrated that fewer patients treated with Camzyos met the criteria for septal reduction therapy (SRT) or chose to have the procedure. Camzyos may address some of the needs that are important to patients by reducing HCM symptoms and improving patients' health-related quality of life (HRQoL). Based on CADTH’s assessment of the health economic evidence, Camzyos does not represent good value to the health care system at the public list price. A price reduction is therefore required. Based on public list prices, Camzyos is estimated to cost the public drug plans approximately $54 million over the next 3 years.

ADDITIONAL INFORMATION

WHAT IS OHCM? HCM is a genetic heart disease that occurs in about 1 in 500 adults and causes increased heart muscle thickness, making it difficult for the heart to pump blood. In oHCM, the thickened part of the heart muscle blocks or reduces the blood flow from the LV to the rest of the body. Associated complications of oHCM include heart failure, stroke, arrhythmias, and sudden cardiac death. UNMET NEEDS IN OHCM: Patients with oHCM identified a need for treatment options that reduce the risk of heart failure, sudden cardiac death, and the debilitating symptoms that affect their daily living activities and quality of life. Patients also expressed a need for treatments that are noninvasive alternatives to SRT, target the underlying cause of HCM, potentially reverse the course of the disease, and are more efficacious than currently available treatments. HOW MUCH DOES CAMZYOS COST? Treatment with Camzyos is expected to cost approximately $22,484 per year.